APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell-Free Circulating Tumor DNA (ctDNA)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Analysis and Forecast 2026-2032

2 May 2026227 pages

Choose your research edition.

Industry ResearchCell-Free Circulating Tumor DNA (ctDNA) Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell-Free Circulating Tumor DNA (ctDNA) Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market Analysis and Forecast 2026-2032227 pages · $4,950 USD

Market perspective

The global Cell-Free Circulating Tumor DNA (ctDNA) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cell-Free Circulating Tumor DNA (ctDNA) include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis and QIAGEN, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cell-Free Circulating Tumor DNA (ctDNA), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cell-Free Circulating Tumor DNA (ctDNA), also provides the revenue of main regions and countries. Of the upcoming market potential for Cell-Free Circulating Tumor DNA (ctDNA), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cell-Free Circulating Tumor DNA (ctDNA) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cell-Free Circulating Tumor DNA (ctDNA) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cell-Free Circulating Tumor DNA (ctDNA) revenue, projected growth trends, production technology, application and end-user industry.

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Company

Nexomics

Roche

ORIOMICS

Signatera

Illumina

Sysmex Corporation

Bio-Rad

Biocartis

QIAGEN

GuardantHealth

GSK plc

AstraZeneca

NeoGenomics Laboratories

AmoyDx

Annoroad

Burning Rock Biotech

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type

Gastric Cancer Methylation Screening

Esophageal Cancer Methylation Screening

Colorectal Cancer Methylation Screening

Lung Cancer Methylation Screening

Liver Cancer Methylation Screening

Other Cancer Screening

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application

Hospital

Medical Center

Laboratory

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell-Free Circulating Tumor DNA (ctDNA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell-Free Circulating Tumor DNA (ctDNA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell-Free Circulating Tumor DNA (ctDNA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cell-Free Circulating Tumor DNA (ctDNA) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell-Free Circulating Tumor DNA (ctDNA) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Gastric Cancer Methylation Screening Major Player Table 3. Esophageal Cancer Methylation Screening Major Player Table 4. Colorectal Cancer Methylation Screening Major Player Table 5. Lung Cancer Methylation Screening Major Player Table 6. Liver Cancer Methylation Screening Major Player Table 7. Other Cancer Screening Major Player Table 8. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Player Table 10. Medical Center Major Player Table 11. Laboratory Major Player Table 12. Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends Table 13. Cell-Free Circulating Tumor DNA (ctDNA) Industry Drivers Table 14. Cell-Free Circulating Tumor DNA (ctDNA) Industry Opportunities and Challenges Table 15. Cell-Free Circulating Tumor DNA (ctDNA) Industry Restraints Table 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2021-2026) Table 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2027-2032) Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Players (2021-2026) Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Key Players Headquarters & Area Served Table 25. Global Cell-Free Circulating Tumor DNA (ctDNA) Players, Product Type & Application Table 26. Global Cell-Free Circulating Tumor DNA (ctDNA) Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Cell-Free Circulating Tumor DNA (ctDNA) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2021-2026) Table 33. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2027-2032) Table 34. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2021-2026) Table 38. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2027-2032) Table 39. Nexomics Company Information Table 40. Nexomics Business Overview Table 41. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 43. Nexomics Recent Development Table 44. Roche Company Information Table 45. Roche Business Overview Table 46. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 48. Roche Recent Development Table 49. ORIOMICS Company Information Table 50. ORIOMICS Business Overview Table 51. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 53. ORIOMICS Recent Development Table 54. Signatera Company Information Table 55. Signatera Business Overview Table 56. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 58. Signatera Recent Development Table 59. Illumina Company Information Table 60. Illumina Business Overview Table 61. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 63. Illumina Recent Development Table 64. Sysmex Corporation Company Information Table 65. Sysmex Corporation Business Overview Table 66. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 68. Sysmex Corporation Recent Development Table 69. Bio-Rad Company Information Table 70. Bio-Rad Business Overview Table 71. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 73. Bio-Rad Recent Development Table 74. Biocartis Company Information Table 75. Biocartis Business Overview Table 76. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 78. Biocartis Recent Development Table 79. QIAGEN Company Information Table 80. QIAGEN Business Overview Table 81. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 83. QIAGEN Recent Development Table 84. GuardantHealth Company Information Table 85. GuardantHealth Business Overview Table 86. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 88. GuardantHealth Recent Development Table 89. GSK plc Company Information Table 90. GSK plc Business Overview Table 91. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 93. GSK plc Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 98. AstraZeneca Recent Development Table 99. NeoGenomics Laboratories Company Information Table 100. NeoGenomics Laboratories Business Overview Table 101. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 103. NeoGenomics Laboratories Recent Development Table 104. AmoyDx Company Information Table 105. AmoyDx Business Overview Table 106. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 108. AmoyDx Recent Development Table 109. Annoroad Company Information Table 110. Annoroad Business Overview Table 111. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 113. Annoroad Recent Development Table 114. Burning Rock Biotech Company Information Table 115. Burning Rock Biotech Business Overview Table 116. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 118. Burning Rock Biotech Recent Development Table 119. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026) & (US$ Million) Table 120. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032) & (US$ Million) Table 121. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026) & (US$ Million) Table 122. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032) & (US$ Million) Table 123. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021-2026) & (US$ Million) Table 125. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (US$ Million) & (2027-2032) Table 126. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026) & (US$ Million) Table 127. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032) & (US$ Million) Table 128. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026) & (US$ Million) Table 129. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032) & (US$ Million) Table 130. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021-2026) & (US$ Million) Table 132. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (US$ Million) & (2027-2032) Table 133. China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026) & (US$ Million) Table 134. China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032) & (US$ Million) Table 135. China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026) & (US$ Million) Table 136. China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026) & (US$ Million) Table 138. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032) & (US$ Million) Table 139. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026) & (US$ Million) Table 140. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032) & (US$ Million) Table 141. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 142. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Region (US$ Million) & (2021-2026) Table 143. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Region (US$ Million) & (2027-2032) Table 144. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026) & (US$ Million) Table 145. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032) & (US$ Million) Table 146. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026) & (US$ Million) Table 147. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032) & (US$ Million) Table 148. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021-2026) & (US$ Million) Table 150. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (US$ Million) & (2027-2032) Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Cell-Free Circulating Tumor DNA (ctDNA) Image Figure 2. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Gastric Cancer Methylation Screening Image Figure 5. Esophageal Cancer Methylation Screening Image Figure 6. Colorectal Cancer Methylation Screening Image Figure 7. Lung Cancer Methylation Screening Image Figure 8. Liver Cancer Methylation Screening Image Figure 9. Other Cancer Screening Image Figure 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Medical Center Image Figure 14. Laboratory Image Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million) & (2021-2032) Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2021-2032) Figure 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2021-2032) Figure 26. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032) Figure 28. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032) Figure 29. North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Country (2021-2032) Figure 30. United States Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032) Figure 35. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032) Figure 36. Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Country (2021-2032) Figure 37. Germany Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032) Figure 47. China Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032) Figure 48. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032) Figure 50. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032) Figure 51. Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Region (2021-2032) Figure 52. Japan Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032) Figure 60. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032) Figure 61. SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Country (2021-2032) Figure 62. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Gastric Cancer Methylation Screening
  • Esophageal Cancer Methylation Screening
  • Colorectal Cancer Methylation Screening
  • Lung Cancer Methylation Screening
  • Liver Cancer Methylation Screening
  • Other Cancer Screening
Applications
  • Hospital
  • Medical Center
  • Laboratory
Companies covered
  • Nexomics
  • Roche
  • ORIOMICS
  • Signatera
  • Illumina
  • Sysmex Corporation
  • Bio-Rad
  • Biocartis
  • QIAGEN
  • GuardantHealth
  • GSK plc
  • AstraZeneca
  • NeoGenomics Laboratories
  • AmoyDx
  • Annoroad
  • Burning Rock Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cell-Free Circulating Tumor DNA (ctDNA) Market by Type
  3. 1.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Gastric Cancer Methylation Screening
  5. 1.2.3 Esophageal Cancer Methylation Screening
  6. 1.2.4 Colorectal Cancer Methylation Screening
  7. 1.2.5 Lung Cancer Methylation Screening
  8. 1.2.6 Liver Cancer Methylation Screening
  9. 1.2.7 Other Cancer Screening
  10. 1.3 Cell-Free Circulating Tumor DNA (ctDNA) Market by Application
  11. 1.3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Medical Center
  14. 1.3.4 Laboratory
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Cell-Free Circulating Tumor DNA (ctDNA) Market Dynamics
  1. 2.1 Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends
  2. 2.2 Cell-Free Circulating Tumor DNA (ctDNA) Industry Drivers
  3. 2.3 Cell-Free Circulating Tumor DNA (ctDNA) Industry Opportunities and Challenges
  4. 2.4 Cell-Free Circulating Tumor DNA (ctDNA) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Perspective (2021-2032)
  2. 3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Growth Trends by Region
  3. 3.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026)
  5. 3.2.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Players
  2. 4.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Players (2021-2026)
  3. 4.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Key Players Headquarters & Area Served
  7. 4.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Players, Product Type & Application
  8. 4.5 Global Cell-Free Circulating Tumor DNA (ctDNA) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market CR5 and HHI
  11. 4.6.3 2025 Cell-Free Circulating Tumor DNA (ctDNA) Tier 1, Tier 2, and Tier 3
5 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
  1. 5.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2032)
  3. 5.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2021-2032)
6 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
  1. 6.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2032)
  3. 6.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Nexomics
  2. 7.1.1 Nexomics Company Information
  3. 7.1.2 Nexomics Business Overview
  4. 7.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  6. 7.1.5 Nexomics Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 ORIOMICS
  14. 7.3.1 ORIOMICS Company Information
  15. 7.3.2 ORIOMICS Business Overview
  16. 7.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  18. 7.3.5 ORIOMICS Recent Developments
  19. 7.4 Signatera
  20. 7.4.1 Signatera Company Information
  21. 7.4.2 Signatera Business Overview
  22. 7.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  24. 7.4.5 Signatera Recent Developments
  25. 7.5 Illumina
  26. 7.5.1 Illumina Company Information
  27. 7.5.2 Illumina Business Overview
  28. 7.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  30. 7.5.5 Illumina Recent Developments
  31. 7.6 Sysmex Corporation
  32. 7.6.1 Sysmex Corporation Company Information
  33. 7.6.2 Sysmex Corporation Business Overview
  34. 7.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  36. 7.6.5 Sysmex Corporation Recent Developments
  37. 7.7 Bio-Rad
  38. 7.7.1 Bio-Rad Company Information
  39. 7.7.2 Bio-Rad Business Overview
  40. 7.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  42. 7.7.5 Bio-Rad Recent Developments
  43. 7.8 Biocartis
  44. 7.8.1 Biocartis Company Information
  45. 7.8.2 Biocartis Business Overview
  46. 7.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  48. 7.8.5 Biocartis Recent Developments
  49. 7.9 QIAGEN
  50. 7.9.1 QIAGEN Company Information
  51. 7.9.2 QIAGEN Business Overview
  52. 7.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  54. 7.9.5 QIAGEN Recent Developments
  55. 7.10 GuardantHealth
  56. 7.10.1 GuardantHealth Company Information
  57. 7.10.2 GuardantHealth Business Overview
  58. 7.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  60. 7.10.5 GuardantHealth Recent Developments
  61. 7.11 GSK plc
  62. 7.11.1 GSK plc Company Information
  63. 7.11.2 GSK plc Business Overview
  64. 7.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  66. 7.11.5 GSK plc Recent Developments
  67. 7.12 AstraZeneca
  68. 7.12.1 AstraZeneca Company Information
  69. 7.12.2 AstraZeneca Business Overview
  70. 7.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  72. 7.12.5 AstraZeneca Recent Developments
  73. 7.13 NeoGenomics Laboratories
  74. 7.13.1 NeoGenomics Laboratories Company Information
  75. 7.13.2 NeoGenomics Laboratories Business Overview
  76. 7.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  77. 7.13.4 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  78. 7.13.5 NeoGenomics Laboratories Recent Developments
  79. 7.14 AmoyDx
  80. 7.14.1 AmoyDx Company Information
  81. 7.14.2 AmoyDx Business Overview
  82. 7.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  83. 7.14.4 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  84. 7.14.5 AmoyDx Recent Developments
  85. 7.15 Annoroad
  86. 7.15.1 Annoroad Company Information
  87. 7.15.2 Annoroad Business Overview
  88. 7.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  90. 7.15.5 Annoroad Recent Developments
  91. 7.16 Burning Rock Biotech
  92. 7.16.1 Burning Rock Biotech Company Information
  93. 7.16.2 Burning Rock Biotech Business Overview
  94. 7.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  96. 7.16.5 Burning Rock Biotech Recent Developments
8 North America
  1. 8.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue (2021-2032)
  2. 8.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2032)
  3. 8.2.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026)
  4. 8.2.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032)
  5. 8.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032)
  6. 8.4 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2032)
  7. 8.4.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026)
  8. 8.4.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032)
  9. 8.5 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032)
  10. 8.6 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country
  11. 8.6.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021-2026)
  13. 8.6.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue (2021-2032)
  2. 9.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032)
  5. 9.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032)
  9. 9.5 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country
  11. 9.6.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue (2021-2032)
  2. 10.2 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2032)
  3. 10.2.1 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026)
  4. 10.2.2 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032)
  5. 10.3 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032)
  6. 10.4 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2032)
  7. 10.4.1 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026)
  8. 10.4.2 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032)
  9. 10.5 China Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue (2021-2032)
  2. 11.2 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032)
  5. 11.3 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032)
  9. 11.5 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country
  11. 11.6.1 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue (2021-2032)
  2. 12.2 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country
  11. 12.6.1 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst